Brenda A. Schulman, Ph.D.


Brenda A. Schulman, Ph.D.
Brenda Schulman
Investigator, Howard Hughes Medical Institute
Department of Genetics/Tumor Cell Biology
St. Jude Children's Research Hospital
MS 311 Room D-5024E
262 Danny Thomas Place
City, State, ZIP
Memphis, TN 38105
(901) 495-5147
[email protected]
Research field
Award year


The Schulman lab studies the structural basis for post-translational modification by ubiquitin and ubiquitin-like proteins (Ubls). Post-translational covalent attachment of Ubls to protein targets is a primary eukaryotic regulatory mechanism. There are more than a dozen Ubls in higher eukaryotes, such as ubiquitin, NEDD8, ISG15, and SUMO, that covalently modify myriad substrates. The best understood function of a Ubl modification is ubiquitin-mediated proteasomal degradation. However, different Ubls alter the functions of their targets in different ways, such as by changing the target’s subcellular localization, enzymatic activity, or interactions with other proteins or DNA. Moreover, defects in these pathways have been widely associated with diseases such as cancer, neurodegenerative disorders and viral infections. We believe that determining the mechanisms by which enzymes transfer Ubls will be of broad importance, much like studies of protein kinases have influenced our knowledge of signaling pathways and their roles in diseases. Toward this end, the goals of our research are (1) to understand the basic enzymatic mechanisms underlying Ubl attachment to targets, (2) to understand how Ubls are attached selectively, and (3) to understand mechanisms by which Ubl covalent attachment can change enzyme and target function.

Search Pew Scholars